Kornimate/medical-research-clean huggingface dataset:
hydrogen-rich water and metabolic health in adults: a 12-week randomized trial

Conditions: Metabolic Syndrome

Summary: the hydro-respond trial is a 12-week randomized controlled study investigating the effects of daily hydrogen-rich water (hrw) consumption on body composition and metabolic biomarkers in adults diagnosed with metabolic syndrome. the study also explores whether individual differences in baseline breath hydrogen levels influence response to hrw. participants are randomly assigned to receive either hrw or a placebo, with outcomes including changes in body fat, waist circumference, glucose metabolism, lipid profiles, and inflammatory markers. the trial aims to determine the therapeutic potential of hrw and identify predictors of individual responsiveness.


Eligibility criteria:
inclusion criteria: * age 30-65 years * metabolic syndrome (nhs) (at least 3 of the 5 following criteria): * waist circumference of ≥ 102 cm in men and ≥ 88 cm in women * hypertriglyceridemia (≥ 1.695 mmol/l) * low hdl-c (\< 1.04 mmol/dl in men and \< 1.30 mmol/dl in women) * high blood pressure (\> 130/85 mmhg) * high fasting glucose (\> 6.1 mmol/l) * not physically active * informed consent signed exclusion criteria: * major chronic disease and acute injuries * history of dietary supplement use during the past 4 weeks * history of metabolism-modulating pharmaceuticals use during the past 4 weeks * no consent to randomization * participation in other studies
noninvasive brain stimulation for treating carpal tunnel syndrome

Conditions: Chronic Pain; Carpal Tunnel Syndrome

Summary: the purpose of this study is to assess the effects of tdcs in combination with tus for the treatment of pain in subjects with carpal tunnel syndrome. the investigators hypothesize that there will be a decrease in pain levels with active stimulation, when compared to sham stimulation.


Eligibility criteria:
inclusion criteria: 1. able to provide informed consent to participate in the study 2. subjects between 18 to 80 years old 3. having symptomatic cts spreading within or beyond the median nerve distribution (demonstrating 'extra-median spread'), involving at least 1 wrist, with chronic pain as defined by international association for the study of pain (existing pain for at least 6 months and having pain on at least half the days in the past 6 months with an average of at least a 3 on a 0-10 vas scale). 4. pain resistant to first line therapies of chronic pain (pain still present at lower levels most of the time following therapy) 5. must have the ability to feel pain as self-reported. exclusion criteria: 1. subject is pregnant 2. contraindications to tdcs+tus: 1. intracranial metal implant 2. implanted brain medical devices 3. history of alcohol or drug abuse within the past 6 months as self-reported 4. use of carbamazepine within the past 6 months as self-reported 5. suffering from major depression (with a phq-9 score of ≥20) 6. history of neurological disorders involving stroke, brain tumors, or epilepsy with residual neurological symptoms as self-reported (note patients will also be evaluated via eeg at baseline about 1 week prior to stimulation and any patient showing abnormal eeg activity will be removed)) 7. history of unexplained fainting spells as self-reported 8. history of head injury resulting in more than a momentary loss of consciousness as self-reported and with current neurological deficits 9. history of intracranial neurosurgery as self-reported

Keywords: transcranial direct current stimulation transcranial ultrasound noninvasive brain stimulation
concurrent nab-p/carboplatin and thoracic radiotherapy in squamous cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell

Summary: nab-paclitaxel and carboplatin showed better treatment response compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer, especially for squamous cell cancer. the regimen of weekly nab-paclitaxel, carboplatin and concurrent radiotherapy was well tolerated in a phase i study. given nab-paclitaxel, carboplatin and concurrent radiotherapy in patients with local advanced squamous cell lung cancer may have promising result.

this study was conducted to explore the efficacy and toxicity of concurrent chemoradiotherapy with nab-paclitaxel, carboplatin and thoracic radiotherapy in unresectable local advanced squamous cell lung cancer. patients will be given nab-paclitaxel weekly at a dose of 60mg/m2, in combination with carboplatin (auc 2) weekly during concurrent chemoradiotherapy. thoracic radiation was administered at a dose of 66 gy/33 fractions, both 3 dimensional conformal and intensity modulated radiation therapy are allowed. two cycles of consolidation therapy with full dose nab-paclitaxel (260 mg/m2 on day 1) and carboplatin (auc 6 on day 1) every 21 day will be delivered.

Eligibility criteria:
inclusion criteria: * performance status of 0 to 1 on the eastern cooperative oncology group (ecog) scale. * previously untreated, histological documented, inoperable stage iiia or iiib squamous cell carcinoma of lung, excluding those with pericardial, pleural effusion, and those with contralateral hilar or contralateral supraclavicular lymph nodes. * patients must have measurable disease according to recist criteria, and all detectable tumor can be encompassed by radiation therapy fields. * weight loss ≦ 5% in the previous six months. * patient must have adequate blood, liver, lungs and kidney function within the requirements of this study. * female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug. * patients must sign a study-specific informed consent form prior to study entry. exclusion criteria: * complete tumor resection, recurrent disease, or those patients eligible for definitive surgery. * previous chemotherapy or previous biologic response modifiers for current lung cancer. * patient has previously had thoracic radiation therapy. * prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for five years or more. * serious concomitant disorders that would compromise the safety of the patient, or compromise the patient's ability to complete the study, at the discretion of the investigator. * history of significant neurological or mental disorder, including seizures or dementia.

Keywords: squamous cell lung cancer radiation therapy chemotherapy
an exploratory pet-study of deposition, disposition and brain uptake of [11c]nicotine after inhalation of 2 nicotine formulations via the myblutm e-cigarette in smokers

Conditions: Healthy Volunteers

Summary: this is a single-center, exploratory positron emission tomography (pet) study of deposition, disposition and brain uptake \[11c\]nicotine when given to smokers as two different formulations via myblutm e-cigarette system.


Eligibility criteria:
inclusion criteria: * body mass index ≥18.0 and ≤ 30.0 kg/m2 * habitual daily cigarette smoker * women have to be of non-child bearing potential exclusion criteria: * history of any clinically significant disease * relevant concomitant medication * any clinically significant condition * malignancy within the past 5 years * positif for hiv, hepatitis b or c * untreated hypertension * previous participation to a pet-study or other nuclide medical study * previous exposure to significant radiation * negative results of the modified allen test on both arms at screening * alcohol or drug abuse
relationship of cerebral perfusion pressure variability to sepsis-associated encephalopathy

Conditions: Sepsis

Summary: the purpose of the study is to evaluate whether variability of cpp (cerebral perfusion pressure) is related to sepsis-associated encephalopathy and outcomes of patients with sepsis.

encephalopathy is a common complication of sepsis, impaired cerebrovascular autoregulation (ar) in patients with sepsis is considered related to sepsis-associated encephalopathy (sae). as ar is important in stabilizing the cerebral perfusion pressure, whether greater variability of cpp is related to sae and mortality or not remains unclear. we conduct this study to evaluate the relationship between them.

Eligibility criteria:
inclusion criteria: * clinical symptoms of sepsis, severe sepsis and septic shock * age over 18 years exclusion criteria: * preexisting neurological diseases * traumatic brain injury * intracranial infectious disease * severe hepatic or renal dysfunction * icu discharge within 72 hours * pregnancy

Keywords: cerebral perfusion pressure septic encephalopathy
stem cells treatment for extremely complex fistulae (hulpcir)

Conditions: Extremely Complex Perianal Fistulae

Summary: the purpose of this study is to evaluate the practicability of the autologous e-asc (autologous stem cells) for the treatment of extremely complex and treatment resistant perianal fistulae.


Eligibility criteria:
inclusion criteria: * signed informed consent * extremely complex perianal fistulae * men and women over 18 years old. good general state of health according to the findings of the clinical history and the physical examination * previous failure in at least one closing fistula standard treatment exclusion criteria: * presence of severe proctitis or dominant active luminal disease requiring immediate therapy * patients with an abscess unless a complete toilet of the area with drainage of the collections and the absence of abscess and other collections is confirmed prior to treatment start * patients with a history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion * patients with malignant tumor, except for basal cell or cutaneous squamous cell carcinoma, or patients with a prior history of malignant tumors, unless the neoplastic disease has been in remission for the previous 5 years * patients with cardiopulmonary disease which, in opinion of the investigator, in unstable or sufficiently serious to exclude the patient from the study. * patients with any type of medical or psychiatric disease which, in the opinion of the investigator, could be grounds for exclusion from study * patients with congenital or acquired immunodeficiencies. hiv, hbv, hcv or treponema infection, whether active or latent * patients who have suffering major surgery or severe trauma in the prior 6 months * pregnant or breastfeeding women * patients currently receiving, or having received within 1 month prior to enrollment into this clinical trial, any investigational drug

Keywords: extremely complex perianal fistula adipose derived stem cells
postoperative recovery index, patient expectations and satisfaction with prenatal care instrument in pregnant patients with covid-19

Conditions: COVID-19; Prenatal Care; Postoperative Care

Summary: the aim of this study is to provide optimum care to postoperative patients diagnosed with covid-19 (after cesarean) and to help them with recovery, to determine and assist the expectation and satisfaction of pregnant women with covid-19 regarding prenatal care.


Eligibility criteria:
inclusion criteria: * pregnant patients with covid-19 exclusion criteria: * patient giving preterm labor

Keywords: covid-19 prenatal care postoperative care
acquisition of 3d facial geometry of patients' scheduled for radiotherapy treatment

Conditions: Head and Neck Cancer

Summary: this study investigates the feasibility of using 3d-printing to manufacture masks used to immobilize patients undergoing radiotherapy treatment for tumors affecting the head and neck.

the current types of masks that are used in radiotherapy treatment sessions for those patients who have head-and-neck cancer are 'made to measure' and the methods currently employed to make them are invasive and in some cases patients' have found this to be particularly unpleasant. their experience motivates research into less invasive and potentially more accurate techniques for their manufacture. to effectively develop an automatic manufacturing pipeline, and to assess the accuracy of the approach we need access to ct data from a cohort of patients for which we also have an accurate (ground truth) 3d facial model. such a model can be acquired in a few minutes using a hand-held laser scanner.

Eligibility criteria:
inclusion criteria: * have a head-and-neck cancer * receiving radiotherapy treatments (ct images) exclusion criteria: * children (age less than 18)

Keywords: head and neck cancer radiotherapy
clinical trial of a therapeutic vaccine with ny-eso-1 in combination with the adjuvant monophosphoryl lipid a (mpla)

Conditions: Cancer.; Melanoma.; Ovarian Cancer.; Lung Cancer.

Summary: this study is a clinical trial phase i/ii. its goal is to determine the safety, tolerability, immunogenicity and efficacy of a therapeutic vaccine with the tumor antigen ny-eso-1 combined with the adjuvant mpla from b. pertussis in cancer patients.

the safety and immunogenicity of the vaccine with the antigen ny-eso-1 in combination with the mpla will be evaluated in a phase 1 clinical trial conducted in patients with malignancies that express the antigen (lung, ovarian and melanoma). this study will involve 15 patients, who will receive 250 mcg of ny-eso-1 and 100 mcg of mpla.

Eligibility criteria:
inclusion criteria: * in this study, will be included fifteen patients aged over 18 years, with a confirmed diagnosis of malignant neoplasms, which have proven ny-eso-1 expression by immunohistochemistry and have undergone the standard treatment. exclusion criteria: * will be excluded from the study patients with continuous use of systemic steroids, immunosuppressive agents and antibiotics, and with severe chronic systemic disease.

Keywords: cancer. melanoma. ovarian cancer. lung cancer. ny-eso-1. mpla (monophosphoryl lipid a). tumor antigen. bordetella pertussis.
project quest 2023: queer survivors of trauma

Conditions: Stress Disorders, Post-Traumatic; Drinking Heavy

Summary: this study aims to test the initial efficacy of tailored online writing interventions specifically designed for sexual minority women, transgender individuals, and/or nonbinary people to target the primary outcomes: posttraumatic stress disorder (ptsd) symptom severity and hazardous drinking.

this study aims to provide a novel method for adapting and testing evidence-based expressive writing (ew) treatments for trauma-exposed sexual minority women (smw) and gender diverse individuals. the investigators will (1) describe the development and components of the proposed ew treatments, (2) discuss our plan for evaluating acceptability and feasibility of the proposed study, (3) identify steps for characterizing preliminary efficacy of ew treatments in reducing ptsd symptom severity and hazardous drinking levels compared to control, and (4) highlight our strategy for preliminarily evaluating mediators and moderators of treatment efficacy.

Eligibility criteria:
inclusion criteria: * being at least 18 years of age * reporting english fluency * identifying as sexual minority women, inclusive of gender-diverse people * living in the united states (us) * reporting one or more criterion a traumatic events * having internet and email access * not having received inpatient psychiatric support in the past six months exclusion criteria: * failing an inclusion criterion

Keywords: sexual trauma ptsd symptoms coping lgbtq lesbian bisexual sexual and gender minorities alcohol-related disorders
immune repertoire of ovarian hgsc

Conditions: Ovarian High Grade Serous Carcinoma; Immune Repertoire; T Lymphocyte Receptor; B Lymphocyte Receptor

Summary: in this preliminary study, peripheral blood and carcinoma tissue with pericarcinomatous tissue are taken from the patients with ovarian high grade serous carcinoma at several points: before any treatment, after the debulking surgery, and after all the proposed chemotherapy. the differential expression of the t/b lymphocyte receptors in these samples will be analyzed with the platinum-based treatment and survival outcomes of the patients. the primary objective is the expression rates of t/b lymphocyte receptors in different stages of checking points.


Eligibility criteria:
inclusion criteria: * confirmed of primary ovarian high grade serous carcinoma * aged 18 years or older * no immunosuppressive disease * signed an approved informed consents exclusion criteria: * not meeting all of the inclusion criteria
laterally wedged insoles for patients with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: knee osteoarthritis is a common problem with the disease prevalence increasing with advancing age. this study will be performed in the purpose of determination the effects of laterally wedged insoles on symptoms reduction of patients with knee osteoarthritis.

knee osteoarthritis is a common problem with the disease prevalence increasing with advancing age. because of the high incidence of knee osteoarthritis in the elderly and the seriousness of drug effects in this age group and lack of controlled study in our country regarding the possible benefits or lack of benefit of laterally wedged insoles in patients with knee osteoarthritis and also due to strike, and results of mixed in other studies, this study will be performed in the purpose of determination the effects of laterally wedged insoles on symptoms reduction of patients with knee osteoarthritis.

Eligibility criteria:
inclusion criteria: * symptomatic medial femorotibial knee oa, * daily knee pain for at least 1 month in the last 3 months, * radiographic evidence of medial femorotibial knee oa, * normal erythrocyte sedimentation rate. exclusion criteria: * secondary knee oa, hip oa, symptomatic foot deformities, articular space loss more or the same as lateral femorotibial side in radiography, * knee joint lavage in past 3 months, * intra-articular corticosteroid injection during the past 3 months, * tibial osteotomy during last 5 years and changes in drug treatment for oa during last week.

Keywords: joint diseases arthritis osteoarthritis
combination of chest scanography and nasal viral detection test to detect covid-19 positive patients before surgical intervention in a university hospital during coronavirus pandemia

Conditions: COVID 19; SARS-Cov-2

Summary: this research aims to improve the screening for covid-19 upon admission to the montpellier university hospital for an act under general anesthesia or at high risk of transmission of the virus. indeed, routine nasal swabs present many false negatives (60 to 70%) and many patients with the coronavirus have little or no symptoms. performing a chest ct scan can reveal early signs very suggestive of viral pneumoniae due to the new coronavirus without additional risk compared to a simple chest x-ray (no injection of contrast medium, low exposure). the objective is to assess the sensitivity of the diagnosis of covid-19 by carrying out a nasopharyngeal rt-pcr and a low dose thoracic scanography at the hospital admission of patients scheduled to a procedure under general anesthesia or at risk of aerosolization (surgery, endoscopy, procedures involving risk of interventional radiology) in order to limit the risks of transmission to healthcare professionals or other patients and to rationalize the use of protective equipment. this is an observational research without modification of care in the setting of covid-19 pandemia. all clinical and biological data will be issued from routine care and medical charts. routine use of ct scan and nasal swabs is an institutional approved strategy. serologic tests will be performed as soon as available from serum collection collected after routine blood analysis. all data will be anonymously recorded after information and non-opposition of the patient.


Eligibility criteria:
inclusion criteria: * scheduled or unscheduled surgical or interventional procedure with at least one night in hospital * chest ct-scan within the first 24 hours * nasopharyngeal swaps within 24 hours before or after hospital admission exclusion criteria : * age under 18 years * patient with restriction of freedom * vital surgical emergency * direct admission to the covid dedicated hospital * opposition to data utilization

Keywords: covid-19 infection or paucy-symptomatic carriage in-hospital screening chest ct-scan
efficacy and safety of abatacept combined with jak inhibitor for refractory rheumatoid arthritis

Conditions: Abatacept; Treatment Compliance; Rheumatoid Arthritis

Summary: the aim of this study is to observe the clinical efficacy and safety of abatacept combined with jak inhibitor in the treatment of d2tra patients


Eligibility criteria:
inclusion criteria: 1. meet the above diagnostic criteria for refractory rheumatoid arthritis 2. the traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease-improving anti-rheumatic drugs is ineffective, and abatacept combined with a jak inhibitor is required treated patients exclusion criteria: 1. patients with tumors, hematological diseases, and other autoimmune diseases 2. those who have a history of allergies to the drugs selected in this study 3. those who cannot adhere to abatacept combined with jak inhibitor therapy, or who have serious adverse reactions and did not complete the observation period prescribed by the study
neuromuscular control in knee osteoarthritis

Conditions: Osteoarthritis Knee

Summary: arthritis is one of the most prevailing causes of disability with knee osteoarthritis (koa) the most common form. the lifetime risk of developing symptomatic koa by the age of 85 years is 44.7%, where females are at a greater risk (1.8 times) than male counter parts. koa is the leading cause of limitations in activities of daily living such as walking and climbing stairs particularly in the elderly. this is primarily due to pain and instability of the joint resulting in buckling of knees caused by muscle weakness, joint stiffness and damage. patients with koa have larger variations in muscle strength and are unable to maintain a target force combined with impaired ability to perceive joint movement and positioning suggests impaired neuromuscular control (nc) may influence koa. nc refers to the nervous system's control over muscle activation contributing to task performance. this study aims to establish the role of loss of nc in biomechanical determinants and health outcomes of koa.


Eligibility criteria:
inclusion criteria: knee osteoarthritis participants only: * knee osteoarthritis confirmed by a physician using the american college of rheumatology (acr 1986) criteria * have unilateral or bilateral knee osteoarthritis * aged 40 years or over. healthy control participants only: * have no history of unilateral/bilateral knee osteoarthritis * had no current chronic/stable knee pain in the past 3 months * aged 40 years or over. exclusion criteria: all participants are excluded if they: * have neuromuscular skeletal injury/illness (e.g.multiple sclerosis, parkinson's disease, muscular dystrophy, cerebral palsy) * have had knee surgery, knee arthroplastic surgery and arthroscopic debridement or corrective surgery for knee osteoarthritis in the past 12 months * have had corticosteroid injections to or around the knee in the past 3 months. * have unstable heart disease * previously had a stroke * have insulin-dependent diabetes * have osteoporosis * have a history of falls and other motor deficits * are unable to walk up and down stairs * are unable to rise from a chair without the aid of another person * have an unstable medication schedule and medication that causes dizziness * have dementia/alzheimer's/ an inability to comprehend, follow instructions and give informed consent * have an inability to lie flat for 60 minutes have mental in their body.

Keywords: osteoarthritis knee